Rett Syndrome (RTT), a progressive neurological disorder characterized by developmental regression and loss of motor and language skills, is caused by mutations in the X-linked gene encoding methyl-CpG binding protein 2 (MECP2). Neurostructural phenotypes including decreased neuronal size, dendritic complexity, and spine density have been reported in postmortem RTT brain tissue and in Mecp2 animal models. How these changes in neuronal morphology are related to RTT-like phenotype and MeCP2 function, and the extent to which restoration of neuronal morphology can be used as a cellular readout in therapeutic studies, however, remain unclear. Here, we systematically examined neuronal morphology in vivo across three Mecp2 mouse models representing Mecp2 loss-of-function, partial loss-of-function, and gain-of-function mutations, at developmental time points corresponding to early-and late-symptomatic RTT-like behavioral phenotypes. We found that in Mecp2 loss-of-function mouse models, dendritic complexity is reduced in a mild, age-dependent, and brain region-specific manner, whereas soma size is reduced consistently throughout development. Neither phenotype, however, is altered in Mecp2 gain-of-function mice. Our results suggest that, in the cell types we examined, the use of dendritic morphology as a cellular readout of RTT phenotype and therapeutic efficacy should be cautioned, as it is intrinsically variable. In contrast, soma size may be a robust and reliable marker for evaluation of MeCP2 function in Mecp2 loss-of-function studies.
Introduction
Rett Syndrome (RTT) is a neurological disorder that is caused by mutations in the X-linked gene encoding methyl-CpG binding protein 2 (MECP2) (Amir et al., 1999) . It primarily affects young girls, with a prevalence of 1 in 10-15,000 live births. One striking feature of RTT is the time course at which clinical symptoms appear. After 6-18 months of apparently normal development, affected individuals enter a period of developmental stagnation, characterized by microcephaly, growth arrest and hypotonia. This stage is followed by a period of developmental regression, where patients display stereotypic hand wringing and social withdrawal, lose acquired motor and speech skills, and develop respiratory abnormalities (Chahrour and Zoghbi, 2007) .
Phenotypic variability is present within the classic RTT profile, where affected girls differ by clinical severity (Chahrour and Zoghbi, 2007) . This variability may be attributed to random X-chromosome inactivation and the variety of MECP2 mutations, including missense, nonsense, deletion, and insertion mutations, that have been identified in RTT patients (Bienvenu and Chelly, 2006) . In vitro biochemical studies have demonstrated that the majority of these mutations lead to Mecp2 loss-of-function (Kriaucionis and Bird, 2003) . Notably, genetic studies have also identified patients carrying duplication or triplication of MECP2 (Bienvenu and Chelly, 2006). These patients are classified under MECP2 duplication syndrome and bear a similar but distinct clinical profile to that of classical RTT (Chahrour and Zoghbi, 2007) . Mice carrying two-fold levels of Mecp2 expression also show behavioral abnormalities (Collins et al., 2004; Luikenhuis et al., 2004) , highlighting the importance of MeCP2 dosage and the detrimental effect of Mecp2 gain-of-function.
Histological analysis of postmortem RTT brain tissue has revealed morphological phenotypes including decreased cellular size with increased cell-packing density (Bauman et al., 1995) , decreased dendritic complexity (Armstrong, 2005; Belichenko et al., 1994) , and decreased spine density (Belichenko et al., 1994; Chapleau et al., 2009 ). Interestingly, these changes are selective, as decreased dendritic complexity has been observed in the motor, frontal, and inferior temporal cortices, but not in the visual cortex or hippocampus (Armstrong et al., 1995) . Moreover, these changes appear to be cortical layer-specific, even within the same cortical area (Armstrong et al., 1995) . No evidence of neuronal degeneration or atrophy has been identified (Armstrong, 2005; Jellinger et al., 1988) , indicating that these morphological changes are a consequence of impaired neuronal development or structural maintenance, rather than neurodegeneration. What remains unclear, however, is how mutations in MECP2 lead to these changes in neuronal Neurobiology of Disease 58 (2013) 3-12 
